Olympia Kovich, MD
Dermatopathology · Plainville, MANPI 1558312272
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 53.1% of the total. Reporting peaked in 2019 at $97 and has fallen 85.1% since, to $15 in 2025.
Across 8 payments — averaging $27.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$117
- UCB, Inc.$20
- Novartis$19
- Sun Pharmaceutical Industries Inc.$18
- Sanofi$18
- Organon$15
- plus $14 from 1 others
What the payments were for
- Food & beverage$221100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 2 | $117 |
| UCB, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Sanofi | 1 | $18 |
| Organon | 1 | $15 |
| Dermavant Sciences, Inc. | 1 | $14 |
How this compares
Too few dermatopathology providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 12 | $56,055 |
| Ketoconazole | 148 | $3,163 |
| Fluorouracil | 36 | $1,839 |
| Clindamycin Phosphate | 15 | $1,457 |
| Triamcinolone Acetonide | 70 | $926 |
| Betamethasone Dipropionate | 16 | $692 |
| Clobetasol Propionate | 15 | $675 |
| Fluocinonide | 14 | $641 |
| CiclopiroxCiclopirox Olamine | 46 | $501 |
| Tretinoin | 17 | $489 |
| Doxycycline Hyclate | 17 | $384 |
| Mometasone Furoate | 12 | $263 |
| ValacyclovirValacyclovir Hcl | 12 | $181 |
| Mupirocin | 27 | $144 |
| Nystatin | 11 | $142 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Plainville
- Lynn DrakeBoston$46K
- Artur ZembowiczBurlington$5K
- Karen MitchellMarlborough$3K
- Yvana CespedesLexington$1K
- Rosalynn NazarianBoston$1K
- Yvonne HinesAttleboro$750
- Mary TanNeedham$158
- Adriano PirisNeedham$95
- Mandana MahmoodiNeedham$28
- Alejandro Peralta SolerNeedham$28
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.